Aileron Therapeutics Balance Sheet Health
Financial Health criteria checks 6/6
Aileron Therapeutics has a total shareholder equity of $11.2M and total debt of $0.0, which brings its debt-to-equity ratio to 0%. Its total assets and total liabilities are $12.8M and $1.6M respectively.
Key information
0%
Debt to equity ratio
US$0
Debt
Interest coverage ratio | n/a |
Cash | US$12.07m |
Equity | US$11.20m |
Total liabilities | US$1.62m |
Total assets | US$12.82m |
Recent financial health updates
Companies Like Aileron Therapeutics (NASDAQ:ALRN) Could Be Quite Risky
Aug 18Is Aileron Therapeutics (NASDAQ:ALRN) In A Good Position To Deliver On Growth Plans?
Dec 30Recent updates
Companies Like Aileron Therapeutics (NASDAQ:ALRN) Could Be Quite Risky
Aug 18Is Aileron Therapeutics (NASDAQ:ALRN) In A Good Position To Deliver On Growth Plans?
Dec 30Aileron Therapeutics: An Assessment On A Lottery Ticket
Oct 21Aileron Therapeutics: Solving Chemotherapy's Toxicity
May 01Aileron Therapeutics +31% on insider buying more shares
Jan 08Aileron raises $40M via equity offering
Jan 06Aileron Therapeutics EPS in-line
Nov 13Financial Position Analysis
Short Term Liabilities: ALRN's short term assets ($12.8M) exceed its short term liabilities ($1.6M).
Long Term Liabilities: ALRN has no long term liabilities.
Debt to Equity History and Analysis
Debt Level: ALRN is debt free.
Reducing Debt: ALRN had no debt 5 years ago.
Balance Sheet
Cash Runway Analysis
For companies that have on average been loss-making in the past, we assess whether they have at least 1 year of cash runway.
Stable Cash Runway: ALRN has sufficient cash runway for 10 months based on last reported free cash flow, but has since raised additional capital.
Forecast Cash Runway: ALRN is forecast to have sufficient cash runway for 9 months based on free cash flow estimates, but has since raised additional capital.